real-time news and commentary for investors
Tuesday, Oct 16
2012, 11:56 AM
Isis Pharmaceuticals (ISIS -16%) drops after an FDA panel posts briefing documents for its...
Isis Pharmaceuticals (ISIS -16%) drops after an FDA panel posts briefing documents for its Hypercholesterolemia treatment Kynamro. The briefing shows an "unexpected" level of concern because drug, which heads before a panel of non-FDA experts Thursday charged with recommending approval, has shown to cause an increase in cancers in rat studies. Additionally, it's also been attributed to fat buildup in the liver that can lead to long-term damage.